Summary

Laquinimod, an oral immunomodulator under development for the treatment of multiple sclerosis (MS), reduced whole brain atrophy in the ALLEGRO and BRAVO trials [Vollmer T et al. Neurology. 2012]. This study analyzed the effect of laquinimod on the percent volume change in gray and white matter in the phase 3 BRAVO trial [Vollmer T et al. J Neurol. 2014], using a newly developed, longitudinal image analysis technique.